TransCode Therapeutics Inc (NASDAQ: RNAZ) has seen a decline in its stock price by -9.04 in relation to its previous close of 0.36. However, the company has experienced a -42.71% decline in its stock price over the last five trading sessions. prnewswire.com reported 2025-05-08 that 15 patients treated across four escalating dose levels of TTX-MC138 No significant safety or dose limiting toxicities reported 10 patients remain on study with no evidence of disease progression PD analysis at 24 hours post-dosing provides evidence of miR-10b target engagement BOSTON, May 8, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its Phase 1a clinical trial has received their initial dose of TTX-MC138. All cohorts have enrolled at least three patients who have been dosed with TTX-MC138 at least once.
Is It Worth Investing in TransCode Therapeutics Inc (NASDAQ: RNAZ) Right Now?
Additionally, the 36-month beta value for RNAZ is 1.53. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for RNAZ is 20.98M and currently, short sellers hold a 4.95% ratio of that float. The average trading volume of RNAZ on May 08, 2025 was 9.14M shares.
RNAZ’s Market Performance
The stock of TransCode Therapeutics Inc (RNAZ) has seen a -42.71% decrease in the past week, with a -16.73% drop in the past month, and a -97.16% fall in the past quarter. The volatility ratio for the week is 24.23%, and the volatility levels for the past 30 days are at 22.22% for RNAZ. The simple moving average for the last 20 days is -16.56% for RNAZ stock, with a simple moving average of -96.03% for the last 200 days.
RNAZ Trading at -56.44% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.51% of loss for the given period.
Volatility was left at 22.22%, however, over the last 30 days, the volatility rate increased by 24.23%, as shares sank -14.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -90.31% lower at present.
During the last 5 trading sessions, RNAZ fell by -42.46%, which changed the moving average for the period of 200-days by -98.76% in comparison to the 20-day moving average, which settled at $0.3873. In addition, TransCode Therapeutics Inc saw -90.41% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RNAZ
The total capital return value is set at 0.01. Equity return is now at value -490.03, with -268.85 for asset returns.
Based on TransCode Therapeutics Inc (RNAZ), the company’s capital structure generated -0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -348.28. The debt to equity ratio resting at -0.02. The interest coverage ratio of the stock is -584.07.
Currently, EBITDA for the company is -14.03 million with net debt to EBITDA at 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.56.
Conclusion
In conclusion, TransCode Therapeutics Inc (RNAZ) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
